DEPRESSIYANI DAVOLASHDAGI TERAPEVTIK REZISTENTLIK: PATOFIZIOLOGIK MEXANIZMLAR, DIAGNOSTIK MEZONLAR VA ZAMONAVIY YONDASHUVLAR
Keywords:
Kalit so’zlar terapevtik rezistent depressiya, antidepressantlar, patofiziologiya, diagnostika, augmentatsiya, nevromodulyatsiyaAbstract
Annotatsiya Terapevtik rezistent depressiya (TRD) — standart antidepressant
terapiyalariga yetarlicha javob bermaydigan major depressiv buzilishning murakkab
klinik varianti bo‘lib, bemorlarning funktsional natijalari va hayot sifati sezilarli
darajada yomonlashadi. Mazkur maqolada TRDning patofiziologik mexanizmlari,
diagnostik mezonlari, biomarkerlar va zamonaviy terapevtik yondashuvlar ilmiy
jihatdan tahlil qilinadi. Yondashuvlar farmakologik strategiyalar, augmentatsiya
moddalari, nevromodulyatsiya va psixoterapiya ichida ko‘rib chiqiladi.
References
ADABIYOTLAR:
1. Rush, A. J., Trivedi, M. H., Wisniewski, S. R., et al. (2006). Acute and longer-term
outcomes in depressed outpatients requiring one or several treatment steps: A
STARD report. * Am J Psychiatry, 163(11), 1905–1917.
2. Fava, M. (2003). Diagnosis and definition of treatment-resistant depression. Biol
Psychiatry, 53(8), 649–659.
3. Berlim, M. T., Turecki, G. (2007). Definition, assessment, and staging of
treatment-resistant refractory major depression: a review of current concepts and
methods. Can J Psychiatry, 52(1), 46–54.
4. Otte, C., Gold, S. M., Penninx, B. W., et al. (2016). Major depressive disorder. Nat
Rev Dis Primers, 2, 16065.
5. Malhi, G. S., Mann, J. J. (2018). Depression. Lancet, 392(10161), 2299–2312.
6. Gaynes, B. N., Warden, D., Trivedi, M. H., et al. (2009). What did STARD teach
us? Results from a large-scale, practical, clinical trial for patients with depression.
* Psychiatr Serv, 60(11), 1439–1445.
7. Zarate, C. A., Singh, J. B., Carlson, P. J., et al. (2006). A randomized trial of an N-
methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen
Psychiatry, 63(8), 856–864.
8. Carvalho, A. F., Sharma, M. S., Brunoni, A. R., et al. (2016). The integrative role
of inflammation, oxidative stress, and neuroplasticity in treatment-resistant
depression. Prog Neuropsychopharmacol Biol Psychiatry, 64, 281–293.
9. Conway, C. R., George, M. S., Sackeim, H. A. (2017). Toward an evidence-based,
operational definition of treatment-resistant depression: When enough is enough.
JAMA Psychiatry, 74(1), 9–10.
10. McIntyre, R. S., Filteau, M. J., Martin, L., et al. (2014). Cognitive deficits in
treatment-resistant depression: clinical, neuropsychological, and functional
correlates. CNS Spectr, 19(3), 215–222.
11. Ionescu, D. F., Papakostas, G. I., Kulkarni, P., et al. (2015). Emerging targets for
antidepressant therapies in treatment-resistant depression. Nat Rev Drug Discov,
14(11), 731–748.
